echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Chuangsheng Group announced that it will announce the phase I updated clinical data of its pH-dependent PD-L1 antibody MSB2311 at the ASCO conference in 2021

    Chuangsheng Group announced that it will announce the phase I updated clinical data of its pH-dependent PD-L1 antibody MSB2311 at the ASCO conference in 2021

    • Last Update: 2021-07-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Chuangsheng Group, a clinical stage international biopharmaceutical company with the ability to integrate the entire process of biopharmaceutical research and development, clinical and process development and production, today announced that it will pass the abstract online at the 57th American Society of Clinical Oncology (ASCO) The method of publication announced the update of the safety and efficacy data of the phase I clinical study of its pH-dependent PD-L1 antibody MSB2311 in patients with advanced solid tumors and hematological malignancies in China
    .


    This annual meeting will be held in the form of a virtual meeting from June 4 to 8, 2021, Eastern Time


    Published online

    title:

    Updated safety and efficacy of MSB2311 (an Anti-Programmed Death-Ligand 1 Antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase I study.

    Update on the safety and efficacy data of the Phase I clinical study of pH-dependent PD-L1 antibody MSB2311 in patients with advanced solid tumors and hematological malignancies in China

    Abstract Number: e14547

    First author:

    Shen Lin, Doctor of Medicine (Peking University Cancer Hospital)

    About MSB2311:

    MSB2311 is a humanized antibody that binds to PD-L1 in a pH-dependent manner
    .


    PD-L1 is involved in suppressing the immune system response against cancer


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.